Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis.
Sinha S, Gould LJ, Nigwekar SU, Serena TE, Brandenburg V, Moe SM, Aronoff G, Chatoth DK, Hymes JL, Miller S, Padgett C, Carroll KJ, Perelló J, Gold A, Chertow GM. Sinha S, et al. Among authors: perello j. Clin Kidney J. 2021 Jul 6;15(1):136-144. doi: 10.1093/ckj/sfab117. eCollection 2022 Jan. Clin Kidney J. 2021. PMID: 35035944 Free PMC article.
Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis.
Brandenburg VM, Sinha S, Torregrosa JV, Garg R, Miller S, Canals AZ, Bahr D, Joubert PH, Salcedo C, Carroll KJ, Gold A, Perelló J. Brandenburg VM, et al. Among authors: perello j. J Nephrol. 2019 Oct;32(5):811-821. doi: 10.1007/s40620-019-00631-0. Epub 2019 Aug 10. J Nephrol. 2019. PMID: 31401795 Clinical Trial.
Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study.
Raggi P, Bellasi A, Bushinsky D, Bover J, Rodriguez M, Ketteler M, Sinha S, Salcedo C, Gillotti K, Padgett C, Garg R, Gold A, Perelló J, Chertow GM. Raggi P, et al. Among authors: perello j. Circulation. 2020 Mar 3;141(9):728-739. doi: 10.1161/CIRCULATIONAHA.119.044195. Epub 2019 Nov 11. Circulation. 2020. PMID: 31707860 Free article. Clinical Trial.
A novel assay to measure calcification propensity: from laboratory to humans.
Perez MM, Ferrer MD, Lazo-Rodriguez M, Canals AZ, Banon-Maneus E, Campistol JM, Miller S, Garg R, Gold A, Salcedo C, Perelló J. Perez MM, et al. Among authors: perello j. Sci Rep. 2020 Oct 16;10(1):17578. doi: 10.1038/s41598-020-74592-x. Sci Rep. 2020. PMID: 33067536 Free PMC article.
Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis - Subgroup Analyses of the CALIPSO Trial.
Raggi P, Bellasi A, Sinha S, Bover J, Rodriguez M, Ketteler M, Bushinsky DA, Garg R, Perelló J, Gold A, Chertow GM. Raggi P, et al. Among authors: perello j. Kidney Int Rep. 2020 Nov 4;5(12):2178-2182. doi: 10.1016/j.ekir.2020.09.032. eCollection 2020 Dec. Kidney Int Rep. 2020. PMID: 33305110 Free PMC article.
Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification.
Bellasi A, Raggi P, Bover J, Bushinsky DA, Chertow GM, Ketteler M, Rodriguez M, Sinha S, Salcedo C, Garg R, Gold A, Perelló J. Bellasi A, et al. Among authors: perello j. Clin Kidney J. 2019 Oct 30;14(1):366-374. doi: 10.1093/ckj/sfz144. eCollection 2021 Jan. Clin Kidney J. 2019. PMID: 33564440 Free PMC article.
158 results